Investor Relations
Investing in Precision, Purpose, and Scalable Innovation
Lahjavida Bio offers investors a differentiated opportunity to participate early in a first- and potentially best-in-class small-molecule precision oncology platform. Our Dye–Drug Conjugate (DDC) technology is engineered to deliver potent therapies with unprecedented selectivity, reduced systemic toxicity, and lower CMC complexity — positioning Lahjavida as a next-generation alternative to large-molecule ADCs.
Key Investment Advantages
Platform-Stage Potential
A modular system spanning dyes, linkers, and payload classes, enabling multiple oncology programs from a single chemistry engine.
Strong IP Position
Broad composition-of-matter and method-of-use coverage across targeting dyes, linker architectures, and dye-payload conjugates.
Validating Preclinical Signals
Tumor-selective uptake, strong efficacy, and significantly lower toxicity demonstrated in early studies.
IND Filing Within 2.5 Years
A clear, efficient development plan supported by synthetic CMC, favorable stability data, and collaborative preclinical work with Syngene.
Capital Efficiency via Small-Molecule Chemistry
No biologics, cell culture, or cold chain — enabling faster timelines, predictable COGS, and scalable manufacturing.
Potential for Strategic Partnerships
Early-access programs, co-development opportunities, and licensing pathways aligned with pharma interest in targeted delivery platforms.
market opportunity
A Platform Play in a Large and Growing Oncology Market
Lahjavida Bio’s Dye-Drug Conjugate (DDC) platform is designed to sit at the intersection of established chemotherapy utility and next-generation precision oncology—leveraging clinically validated payloads while enabling safer, smarter delivery.
Our Dual Strategy
By combining platform flexibility, small-molecule manufacturability, and broad oncology applicability, Lahjavida Bio aims to create durable value across multiple franchises—not just a single asset. The opportunity is to build a scalable precision-oncology platform that can support both internal pipelines and partnered programs, aligned with the long-term growth of the global oncology market.
Request Investor OverviewInternal Development of Lead Programs
Advance Lahjavida Bio’s lead DDC candidate toward IND and first-in-human (FIH) studies in high-need solid tumors where conventional chemotherapy is still standard of care but limited by systemic toxicity.
Strategic Partnerships & Licensing
Collaborate with biopharma partners to apply the DDC platform to high-value oncology assets, extending portfolio differentiation and creating new therapeutic classes built on targeted delivery.
Enable partners to differentiate crowded portfolios with targeted, small-molecule conjugates that may offer improved efficacy, safety, and commercial positioning versus legacy formulations.